Ott et al. ([@B1]) reported that systemic nitric oxide (NO) synthase (NOS) inhibition with *N*^G^-monomethyl-[l]{.smallcaps}-arginine (L-NMMA) ([@B2]) acutely increased the urinary albumin-to-creatinine ratio in hypertensive patients with type 2 diabetes. The authors did not provide direct evidence of reduced NO synthesis by L-NMMA. The pressor response to the NOS inhibitors L-NMMA, asymmetric dimethylarginine (ADMA), and *N*^G^-nitro-[l]{.smallcaps}-arginine methyl ester (L-NAME) is relatively small, given their low inhibitory potency toward endothelial NOS (eNOS) activity ([@B2]). Release of thromboxane A~2~ (TxA~2~), a potent vasoconstrictor and thromboxane-prostanoid (PT) receptor agonist, and the F~2~-isoprostane 15(*S*)-8-*iso*-prostaglandin F~2α~ (15(*S*)-8-*iso*-PGF~2α~), a vasoconstrictor and functional PT receptor agonist, could also be involved. In mice ([@B3]), L-NAME induced hypertension, caused cardiac hypertrophy, and elevated TxA~2~ and 15(*S*)-8-*iso*-PGF~2α~ synthesis. In hypertensive type 2 diabetic subjects, the angiotensin 2 receptor inhibitor olmesartan reduced blood pressure and 15(*S*)-8-*iso*-PGF~2α~ synthesis without changing eNOS activity and ADMA synthesis ([@B4]). We propose that in the study by Ott et al. ([@B1]), excessive renal TxA~2~ and 15(*S*)-8-*iso*-PGF~2α~ synthesis and PT receptor activation may have contributed to albuminuria ([@B5],[@B6]). Systemic infusion of unspecific eNOS inhibitors such as L-NMMA, L-NAME, or ADMA is not a specific procedure to determine local effects of eNOS inhibition in the kidney.
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